Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Replimune Group, Inc. (REPL) Cash Flow Statement

Replimune Group, Inc. (REPL) generated -$279.1M of operating cash flow over the twelve months to 2026-06-30, spent $1.5M on capital expenditure and had free cash flow of -$280.5M, according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

REPLReplimune Group, Inc.Follow REPL — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
1.1B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
4 Nov, in 11 days
LineFY2020
Mar 20
FY2021
Mar 21
FY2022
Mar 22
FY2023
Mar 23
FY2024
Mar 24
FY2025
Mar 25
FY2026
Mar 26
TTM
Jun 26
Trend
Operating cash flow-60.6-61.4-82.2-128.1-185.5-192.3-280.3-279.1
Capital expenditure6.52.42.32.35.76.74.2-1.5
Free cash flow-67.1-63.8-84.5-130.3-191.1-198.9-284.6-280.5
Stock-based compensation7.711.824.328.134.135.032.3—

USD millions · SEC XBRL

Replimune Group, Inc. — questions

What is Replimune Group, Inc.'s operating cash flow?
-$279.1M over the twelve months to 2026-06-30.
How much does Replimune Group, Inc. spend on capital expenditure?
$1.5M over the twelve months to 2026-06-30.
What is Replimune Group, Inc.'s free cash flow?
-$280.5M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.

Every figure on this page comes from Replimune Group, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.